IDEXX Laboratories (NASDAQ:IDXX) Surpasses Earnings and Revenue Estimates
- IDEXX Laboratories (NASDAQ:IDXX) reported an EPS of $3.63, beating the estimated $3.28 and showcasing a positive surprise of 9.67%.
- The company's revenue reached $1.11 billion, an 11% year-over-year increase, surpassing the Zacks Consensus Estimate by 4.01%.
- IDEXX raised its full-year earnings per share projection to $12.40 to $12.76 and its revenue outlook to between $4.20 billion and $4.28 billion, indicating strong growth prospects.
IDEXX Laboratories (NASDAQ:IDXX), a leading entity in the veterinary diagnostics industry, headquartered in Westbrook, Maine, specializes in providing diagnostic products and services to veterinarians. The company is a key competitor in the medical instruments sector, focusing on innovative solutions for animal health.
On August 4, 2025, IDEXX reported an EPS of $3.63, surpassing the estimated $3.28. This performance exceeded the Zacks Consensus Estimate of $3.31, marking a positive surprise of 9.67%. The company's consistent ability to surpass EPS estimates over the past four quarters highlights its strong financial management and operational efficiency.
IDEXX's revenue for the quarter reached approximately $1.11 billion, exceeding the estimated $1.06 billion. This represents an 11% year-over-year increase, showcasing the company's growth trajectory. The revenue also surpassed the Zacks Consensus Estimate by 4.01%, reflecting robust demand for IDEXX's veterinary diagnostic equipment and services.
Following the strong quarterly performance, IDEXX raised its full-year earnings per share projection to a range of $12.40 to $12.76, up from the previous estimate of $11.93 to $12.43. The company also increased its revenue outlook to between $4.20 billion and $4.28 billion. CEO Jay Mazelsky attributes this success to the company's focus on providing veterinarians with deeper diagnostic insights, enhancing patient care and fostering customer loyalty.
The positive financial results led to a significant surge in IDEXX's stock, with shares climbing over 20% on Monday morning. This increase contributed to a more than 55% rise in IDEXX's stock value in 2025. The company's financial metrics, such as a price-to-earnings (P/E) ratio of approximately 61.70 and a debt-to-equity ratio of 0.73, indicate a strong market position and moderate debt levels, supporting its growth prospects.
| Symbol | Price | %chg |
|---|---|---|
| GNTLF | 1 | 0 |
| PRDA.JK | 2720 | 1.1 |
| DHR-PB | 1261.26 | 0 |
| 2359.HK | 107.9 | 0 |
IDEXX Laboratories Surges 10% on Strong Q4 Earnings and Optimistic 2025 Outlook
IDEXX Laboratories (NASDAQ:IDXX) delivered stronger-than-expected fourth-quarter results, propelling its stock up 10% intra-day today. The pet healthcare company outperformed Wall Street estimates on both earnings and revenue, fueled by consistent growth in its Companion Animal Group (CAG) segment and recurring diagnostic services.
For the quarter, IDEXX reported adjusted earnings per share of $2.62, well above the analyst consensus of $2.39. Revenue climbed 6% year-over-year to $954.28 million, exceeding expectations of $933.38 million. The company’s CAG segment led the way, posting a 6% revenue increase, while recurring revenue from CAG Diagnostics rose 7% organically, demonstrating strong demand for its veterinary testing and diagnostic solutions.
Looking ahead, IDEXX issued an optimistic forecast for 2025, projecting revenue between $4.05 billion and $4.17 billion, reflecting 4-7% reported growth and 6-9% organic growth. Adjusted earnings per share are expected to range from $11.74 to $12.24, reinforcing confidence in continued expansion. The company also anticipates steady volume growth and a 4-4.5% pricing benefit throughout the year, supporting sustained momentum in its core business.
IDEXX Laboratories Surges 10% on Strong Q4 Earnings and Optimistic 2025 Outlook
IDEXX Laboratories (NASDAQ:IDXX) delivered stronger-than-expected fourth-quarter results, propelling its stock up 10% intra-day today. The pet healthcare company outperformed Wall Street estimates on both earnings and revenue, fueled by consistent growth in its Companion Animal Group (CAG) segment and recurring diagnostic services.
For the quarter, IDEXX reported adjusted earnings per share of $2.62, well above the analyst consensus of $2.39. Revenue climbed 6% year-over-year to $954.28 million, exceeding expectations of $933.38 million. The company’s CAG segment led the way, posting a 6% revenue increase, while recurring revenue from CAG Diagnostics rose 7% organically, demonstrating strong demand for its veterinary testing and diagnostic solutions.
Looking ahead, IDEXX issued an optimistic forecast for 2025, projecting revenue between $4.05 billion and $4.17 billion, reflecting 4-7% reported growth and 6-9% organic growth. Adjusted earnings per share are expected to range from $11.74 to $12.24, reinforcing confidence in continued expansion. The company also anticipates steady volume growth and a 4-4.5% pricing benefit throughout the year, supporting sustained momentum in its core business.
